|
|
News Breaks
|
January 30, 2012
|
| 16:06 EDT |  | HSP |
| theflyonthewall.com: | Hospira names Richard Davies Chief Commercial Officer | | Hospira announced that Richard Davies has been named senior vice president and chief commercial officer. In this role, he will be responsible for developing and executing Hospira's global commercial strategies and delivering profitable revenue growth across the company's product portfolio. Mr. Davies will join Hospira Feb. 2 and serve as a member of Hospira's senior leadership team, reporting to F. Michael Ball, CEO. :theflyonthewall.com |
|
|
News For HSP From The Last 14 Days Check below for free stories on HSP the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 25, 2012
|
| 06:07 EDT | | HSP |
| theflyonthewall.com: | Theravance to transfer certain technology related to VIBATIV to Hospira | | On May 22, Theravance (THRX) signed a Technology Transfer and Supply Agreement with Hospira Worldwide (HSP). The Agreement provides for the Company to transfer certain manufacturing technology to Hospira related to its VIBATIV drug product, and make technology transfer payments to Hospira as Hospira undertakes and completes technology transfer and validation activities. Once regulatory approval for Hospira to manufacture VIBATIV has been obtained, Hospira will manufacture and sell VIBATIV to the Company pursuant to the Agreement. The Agreement has a five-year term, subject to earlier termination following bankruptcy, uncured breaches or inability to perform. Theravance has agreed, subject to certain conditions and exceptions, to purchase from Hospira more than a majority of its VIBATIV 750 mg dosage form requirements during the term. :theflyonthewall.com |
|
|
May 14, 2012
|
| 06:22 EDT |  | HSP |
| | 06:20 EDT | | HSP |
| theflyonthewall.com: | Hospira initiating recall of Hydrochloride Injection lot, FDA says | | The FDA announced on Saturday that Hospira is initiating a voluntary user level recall of one lot of Hydromorphone Injection due to two reported complaints of a single Carpuject containing more than the 1 mL labeled fill volume. Opioid pain medications such as Hydromorphone have life-threatening consequences if overdosed, the FDA warned. Reference Link :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information